Pipeline
Pipeline
IL-7R Agonist
ɑPD-1 x IL-2/15Rβγ Agonist
IL-7R x IL-2/15Rβγ Agonist
Program
MDK-703
IL-7R Agonist
Phase
Phase 1
Program
Cis-acting
ɑPD-1 x IL-2/15Rβγ Agonist
Phase
Lead Optimization
Program
Dual
IL-7R x IL-2/15Rβγ Agonist
Phase
Lead Optimization
MDK-703
Medikine’s lead candidate MDK-703 is an Fc-fusion protein containing an IL-7 PEPTIKINEᵀᴹ that mimics the therapeutic properties of IL-7, a cytokine critical in the differentiation, maintenance, and survival of T cells. An important feature is its avoidance of the generation of neutralizing antibodies to native IL-7.
Cell-Targeted Agonist
Medikine has identified novel PEPTIKINES that activate the IL-2/15Rβγc with attenuated signaling compared to IL-2. These PEPTIKINES do not bind to the IL-2Rα. Medikine has shown that the potency and cellular specificity of these “attenuated agonists” can be enhanced by fusing them to an anti-PD-1 antibody. Medikine is currently optimizing these unique “cell-targeted” IL-2/15βγc receptor agonists.
Dual Agonist
Using its unique knowledge of the structure-activity relationships of IL-7 and IL-2 PEPTIKINES, and expertise in peptide chemistry, Medikine has created novel synthetic PEPTIKINES that activate the IL-7R and the “non-alpha” IL-2/15Rβγc. Such molecules have the potential benefit of enhancing both memory and effector T-cell populations. Medikine is currently optimizing these unique IL-7R x IL-2/15Rβγc “dual” agonists.